

Successful Treatment of Severe Sinonasal Rosai-Dorfman Disease with the MEK Inhibitor Cobimetinib

Abstract:

Rosai-Dorfman Disease (RDD) is a rare form of non-Langerhans histiocytosis characterized by an accumulation of activated histiocytes in affected tissues. Sinonasal involvement occurs in 11% of RDD cases. Surgical intervention is a common form of management, but has significant limitations in terms of both safety and effectiveness. In this report, we present the case of a 76-year-old woman with severe sinonasal RDD. Over a period of about 8 years, the patient underwent multiple surgical interventions and other treatment modalities, all of which were ineffective. Ultimately, the patient was treated with a partial course of the MEK inhibitor cobimetinib and experienced remarkable clinical improvement. This case report highlights the use of cobimetinib as an effective treatment option for severe sinonasal RDD.